Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid in Renal Cell Cancer with Bone Metastasis
NCT00172003Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2004
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of zoledronic acid in renal cell carcinoma (RCC), bone metastasis, sponsored by Novartis. Started Sep 2004; status: completed.
02
Drugs
zoledronic acid
03
Conditions
renal cell carcinoma (RCC)bone metastasis
Beyond the preview
Go deeper on NCT00172003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00172003.